Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

Clinical trial NCT02301143 · COMPLETED

Trial details

NCT number: NCT02301143
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Neoplasms

Start date: 2015-04-21
Primary completion: 2017-11-21
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.